Blood test may help personalize breast cancer therapy

NCT ID NCT07394218

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a blood test that tracks tumor DNA (ctDNA) can help doctors decide when to intensify treatment for HER2-negative metastatic breast cancer. All 122 participants start with antibody-drug conjugate (ADC) therapy. After two cycles, those whose disease hasn't worsened are split into groups based on how much their ctDNA levels dropped, with some getting additional immunotherapy. The goal is to see if this personalized approach improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Antibody-drug conjugate (ADC) therapy (sacituzumab govitecan or trastuzumab deruxtecan) with or without ivonescimab
What this could lead to
If successful, this could show that monitoring ctDNA levels helps doctors personalize treatment, potentially improving outcomes for people with metastatic breast cancer.
What could go wrong
This is a small, early-phase study (122 people) focused on a biomarker, not a direct treatment comparison. The approach may not improve survival or could add side effects from extra therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTDNA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.